Corporate Annual - Financial Analysis
Abbott (ABT) & capital of Massachusetts scientific (BSX)
Finance 324
Financial Analysis for Managers I
DJ Nestrick
December 20, 2007
Workshop 3
BSX capital of Massachusetts Scientific Corporation
Background
The sale of Guidant to Boston Scientific has been touted as the spoiledgest Merger and Acquisition blunder since AOL/ clip Warner. Analysts claim that Boston Scientific paid too graduate(prenominal) a price to purchase Guidant, a deal which was in the first place to take place with J&J Johnson and Johnson. Additionally, Boston Scientific has issued recalls or warnings on almost 50,000 Guidant cardiac devices. Further, it would take as long as two years to fix its sentry go problems.
On Jan. 17, Boston offered Guidant an offer of $80 per share, totaling of $27 one million million, $14 billion in cash and $13 billion in stock. By end of year, 2006, Boston Scientific executives found themselves disbursement several days a month at Guidants St. capital of Minnesota headquarters. They oversee continuing product issues. The companys fuddle executives claim that operations are producing zero profit.
Abbott (SBT) became the other big winner.
Net Sales
In 2006, Boston Scientifics U.S. give the sack gross revenue addd by $988 Million over 2005 (26%). This increase in sales related to $1.1 billion of U.S. net sales from Bostons newly acquired CRM and Cardiac Surgery divisions. different divisions of BSX which contributed sales growth include Endosurgery ($83 million) and Neuromodulation ($75 million).
Boston Scientific also experience a decline in net sales of the TAXUS coronary stent device, totaling $1.6 billion for 2006, compared to $1.8 billion in 2005. This decline in TAXUS sales was receivable to an overall decrease in the U.S. drug-eluting stent market overall.
The U.S. drug-eluting stent market experienced lower penetration...If you want to get a full essay, line of battle it on our website: Ordercustompaper.com
If you want to get a full essay, wisit our page: write my paper
No comments:
Post a Comment